کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2779543 1153274 2012 5 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی زیست شناسی تکاملی
پیش نمایش صفحه اول مقاله
Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass
چکیده انگلیسی

An acute phase response (APR) is frequently observed in patients treated with intravenous (i.v.) zoledronate (ZOL). We aimed to define clinical and laboratory parameters that may predict ZOL-induced APR in women with low bone mass. Fifty-one postmenopausal women with low bone mass were given a single i.v. infusion of ZOL 5 mg. APR was clinically defined by the visual analog pain scale (VAS) for the musculoskeletal symptoms and body temperature. White blood cell count (WBC), leucocyte subpopulations, C-reactive protein (CRP), parathyroid hormone (PTH), 25-hydroxyvitamin D [25(OH)D], interleukins (IL)-1b and -6, tumor necrosis factor (TNF)α and interferon (IFN)γ were measured before and 48 h following the infusion. Subsequently, patients were divided into those experiencing APR (APR+) or not (APR−). WBC, granulocytes, CRP, IL-1b and IL-6 were significantly increased, whereas lymphocytes, eosinophils, calcium, phosphate and 25(OH)D decreased 48 h after ZOL infusion. Twenty-eight of the 51 patients (54.9%) experienced an APR. APR+ patients were younger and had higher baseline lymphocytes compared to APR− patients. There was no difference (p = 0.405) in the development of APR between treatment-naive patients (19/32, 59.4%) and patients previously treated with another oral nitrogen-containing bisphosphonate (9/19, 47.4%). In conclusion, our data suggest that pre-treatment higher lymphocyte number increases the risk of APR while previous treatment with another nitrogen-containing bisphosphonate does not significantly reduce the risk. Serum 25(OH)D concentrations decrease significantly after the infusion, possibly as part of the inflammatory response to ZOL.


► The incidence of APR following zoledronate depends on criteria used for its definition.
► Prior amino-bisphosphonate use does not significantly reduce risk of zoledronate-induced APR.
► Pre-treatment higher lymphocyte number increases the risk of APR.
► Serum 25(OH)D decreases after the infusion as part of the inflammatory response to zodedronate.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Bone - Volume 50, Issue 5, May 2012, Pages 1130–1134
نویسندگان
, , , , , , , , , , ,